Summary Vopratelimab, an anti-ICOS (inducible costimulator of T cells) agonist, alone and in combination with nivolumab, possesses limited toxicity and modest clinical activity in a large phase I/II trial. This treatment induced ICOS expression of CD4+ T cells, which may enable biomarkers for patient selection. Nevertheless, T-cell agonists as cancer immunotherapies continue to be challenging. See related article by Yap et al., p. 3695

中文翻译：

---

刺激性免疫检查点 ICOS 的困扰

摘要 Vopratelimab 是一种抗 ICOS（T 细胞诱导共刺激剂）激动剂，单独使用或与纳武单抗联合使用，在大型 I/II 期试验中具有有限的毒性和适度的临床活性。这种治疗诱导 CD4+ T 细胞的 ICOS 表达，这可能为患者选择提供生物标志物。然而，T 细胞激动剂作为癌症免疫疗法仍然具有挑战性。参见 Yap 等人的相关文章，第 17 页。3695